Search

Your search keyword '"Berghmans, T."' showing total 692 results
Start Over Author "Berghmans, T."
692 results on '"Berghmans, T."'

6. Comment optimiser le bilan d’opérabilité ?

Author

Falcoz, P.-E., Berghmans, T., Brandao, M., Grigoriu, B., and Charloux, A.

Abstract

La chirurgie reste le traitement central des cancers bronchiques non à petites cellules et des tumeurs carcinoïdes dans les stades limités, et peut être envisagée pour certains cancers à petites cellules. Avant de considérer un patient pour une résection chirurgicale, deux points doivent être envisagés : la résécabilité – la capacité du chirurgien à enlever l’ensemble de la masse tumorale – et l’opérabilité – la capacité du patient à tolérer l’intervention chirurgicale avec une récupération et une qualité de vie suffisantes. La résécabilité dépend du stade d’extension de la maladie néoplasique tandis que l’opérabilité, dont les conséquences sont mesurées en risque opératoire (mortalité et morbidité), prend en compte les caractéristiques du patient : comorbidités, fonctions cardiaque et respiratoire, état général. Cet article évaluera l’opérabilité avec une attention marquée sur le bilan fonctionnel cardiorespiratoire et les algorithmes décisionnels.

Published
2024
Full Text
View/download PDF

7. Cancers bronchiques non à petites cellules de stade III : quel abord local optimal ?

Author

Wolf, J. de, Péchoux, C. Le, and Berghmans, T.

Abstract

Le stade III de la classification TNM internationale représente un groupe hétérogène de maladies dont la prise en charge thérapeutique généralement multimodale est variable, incluant dans la mesure du possible un traitement local, chirurgie ou radiothérapie. De nombreuses études comparant les deux attitudes ont été publiées ne permettant pas de trancher formellement sur l’intérêt – ou son absence – d’inclure une approche chirurgicale dans le traitement multimodal. Un problème majeur dans l’intégration des données issues de ces essais randomisés réside dans l’absence de définition consensuelle sur ce qu’est un stade III résécable, laissée au mieux à l’appréciation du chirurgien et de l’équipe multidisciplinaire en charge du patient.

Published
2024
Full Text
View/download PDF

11. TTFields (Tumor Treating Fields) associés au traitement standard dans les cancers du poumon non à petites cellules métastatiques en progression après platine : étude internationale, randomisée de phase 3 LUNAR

Author

Leal, T., primary, Kotecha, R., additional, Ramlau, R., additional, Zhang, L., additional, Milanowski, J., additional, Cobo, M., additional, Roubec, J., additional, Petruzelka, L., additional, Havel, L., additional, Kalmadi, S., additional, Ward, J., additional, Andric, Z., additional, Berghmans, T., additional, Gerber, D.E., additional, Kloecker, G., additional, Panikkar, R., additional, Aerts, J., additional, Delmonte, A., additional, Pless, M., additional, and Langer, C., additional

Published
2024
Full Text
View/download PDF

16. OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

Author

Houda, I., primary, Bahce, I., additional, Dickhoff, C., additional, Kroese, T.E., additional, Kroeze, S.G.C., additional, Mariolo, A.V., additional, Tagliamento, M., additional, Moliner, L., additional, Brandao, M., additional, Edwards, J., additional, Opitz, I., additional, Faivre-Finn, C., additional, de Ruysscher, D., additional, Remon, J., additional, Berghmans, T., additional, Dingemans, A.-M.C., additional, Besse, B., additional, and Hendriks, L.E.L., additional

Published
2023
Full Text
View/download PDF

17. OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

Author

Leal, T., primary, Kotecha, R., additional, Ramlau, R., additional, Zhang, L., additional, Milanowski, J., additional, Cobo, M., additional, Roubec, J., additional, Petruzelka, L., additional, Havel, L., additional, Kalmadi, S., additional, Ward, J., additional, Andric, Z., additional, Berghmans, T., additional, Gerber, D.E., additional, Kloecker, G., additional, Panikkar, R., additional, Aerts, J., additional, Delmonte, A., additional, Pless, M., additional, Greil, R., additional, Rolfo, C., additional, Akerley, W., additional, Eaton, M., additional, Iqbal, M., additional, and Langer, C., additional

Published
2023
Full Text
View/download PDF

18. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

Author

Brandao, M., primary, Prisciandaro, E., additional, Xenophontos, E., additional, Mariolo, A., additional, Sadeghi, A.H., additional, Filippi, A.R., additional, Levy, A., additional, Bandura, A., additional, Caramella, C., additional, Dickhoff, C., additional, de Margerie-Mellon, C., additional, Faivre-Finn, C., additional, Portik, D., additional, Sanchez-Lorente, D., additional, De Ruysscher, D., additional, Smit, E., additional, Gobbini, E., additional, Fadel, E., additional, Ruffini, E., additional, Olmetto, E., additional, Cortiula, F., additional, Bahce, I., additional, Houda, I., additional, Opitz, I., additional, Naidoo, J., additional, Edwards, J., additional, Remon, J., additional, Benitez, J.C., additional, Trujillo, J.C., additional, Derks, J., additional, Amrane, K., additional, Hartemink, K., additional, Stathopoulos, K., additional, Hendriks, L., additional, Iglesias, M., additional, Occhipinti, M., additional, Guckenberger, M., additional, Giaj Levra, N., additional, Girard, N., additional, Reguart, N., additional, Mercier, O., additional, Bironzo, P., additional, Hofman, P., additional, Horsleben Petersen, R., additional, De Angelis, R., additional, Abgral, R., additional, Terrisse, S., additional, Popat, S., additional, Pierret, T., additional, Gerriet Blum, T., additional, Ricardi, U., additional, Dionisi, V., additional, Berghmans, T., additional, and Dingemans, A.-M., additional

Published
2023
Full Text
View/download PDF

19. P1.28-08 Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group

Author

Xenophontos, E., primary, Giaj Levra, N., additional, Durieux, V., additional, Van Geffen, W., additional, Grisay, G., additional, De la Pinta Alonso, C., additional, Arasanz Esteban, H., additional, Prisciandaro, E., additional, Ferrara, R., additional, Derks, J., additional, Von der Thusen, J., additional, Dickhoff, C., additional, Brandao, M., additional, Faivre-Finn, C., additional, Edwards, J., additional, De Ruysscher, D., additional, Remon, J., additional, Dingemans, A.-M., additional, and Berghmans, T., additional

Published
2023
Full Text
View/download PDF

36. Imaging

Author

Berghmans, T., Bosmans, J., Sculier, Jean-Paul, editor, and Fry, Willard A., editor

Published
2004
Full Text
View/download PDF

37. Exercise in lung Cancer, the healthcare providers opinion (ECHO): Results of the EORTC lung cancer Group (LCG) survey

Author

Pilotto, S., Avancini, A., Menis, J., Sperduti, I., Levra, M.G., Berghmans, T., Bironzo, P., Brandao, M., De Ruysscher, D., Edwards, J., Faivre-Finn, C., Girard, N., Greillier, L., Hendriks, L., Lantuejoul, S., Mauer, M., Novello, S., O'Brien, M., Reck, M., Reguart, N., Remon, J., von der Thusen, J., Dingemans, A.M.C., Besse, B., Milella, M., Pilotto, S., Avancini, A., Menis, J., Sperduti, I., Levra, M.G., Berghmans, T., Bironzo, P., Brandao, M., De Ruysscher, D., Edwards, J., Faivre-Finn, C., Girard, N., Greillier, L., Hendriks, L., Lantuejoul, S., Mauer, M., Novello, S., O'Brien, M., Reck, M., Reguart, N., Remon, J., von der Thusen, J., Dingemans, A.M.C., Besse, B., and Milella, M.

Abstract

Objectives: Exercise has been reported to alleviate disease as well as treatment impact in patients with lung cancer. Nevertheless, there is limited information available regarding the perception of lung cancer dedicated healthcare professionals' and their advice on exercise. Materials and Methods: An online survey exploring healthcare professionals' practice patterns, perceptions, barriers, and facilitators of exercise in patients with lung cancer was conducted within members of the EORTC Lung Cancer Group (LCG).Results: One hundred forty-one healthcare providers completed the survey, mainly medical and radiation oncologists. Overall, 63% of the study participants declared that they frequently assessed exercise level in their patients, and 43% of them reinforced the importance of exercise. However, only 10% referred patients to an exercise program or specialist. Although the majority of the respondents had a positive perception regarding the benefits and safety of exercise (even in patients with advanced disease and/or bone metastasis), two-thirds of clinicians reported not having adequate training about exercise counselling. Moreover, 53% reported to lack of knowledge of guidelines referring to exercise in patients with cancer. Several obstacles and facilitators to improve exercise promotion in lung cancer care were identified.Conclusion: Healthcare providers recognize the relevance and feasibility of exercise as part of cancer treatment intervention, but specific pathways to do the referral are frequently missing. Future structured and well-designed strategies and initiatives are needed to support an effective referral in order to implement exercise interventions routinely in clinical practice.

Published
2022

41. Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer

Author

Berghmans T, Remmelink M, and Awada A

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Thierry Berghmans,1 Myriam Remmelink,2 Ahmad Awada31Clinic of Thoracic Oncology and Department of Intensive Care, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 2Department of Pathology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 3Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BelgiumAbstract: Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the standard of care for patients in whom tumors are presenting with an activating epidermal growth factor-receptor mutation, with new active agents like afatinib reaching clinics in the near future. Other genetic abnormalities have been documented in squamous and non-squamous lung cancer. The EML4–ALK gene fusion is a rare event, occurring in around 5% of lung cancer, quite exclusively in adenocarcinoma with a predominance of young non/light smokers. Detection of ALK-positive tumors is challenging, as there is no gold-standard technique. Fluorescence in situ hybridization is the method used in prospective trials assessing the activity of crizotinib and is recommended by the American FDA. Crizotinib is the first orally active inhibitor of receptor tyrosine kinases, including ALK and ROS1, in clinical practice. Impressive results came from a phase I study and are now confirmed in a large phase II study with response rate of 60%, whatever the number of previous lines of chemotherapy. Other ALK inhibitors are currently in the preclinical phase, and some are showing promising results in early phase I/II studies. This review aims to present the current knowledge on the EML4–ALK gene fusion, the pitfalls for the pathologist and the clinician in searching this abnormality, and to review the existing literature on ALK inhibitors under development, focusing their role compared to chemotherapy in non-small cell lung cancer patients.Keywords: non-small cell lung cancer, EML4–ALK, crizotinib

Published
2012

42. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA

Author

Remon, Jordi, primary, Lacas, Benjamin, additional, Herbst, Roy, additional, Reck, Martin, additional, Garon, Edward B., additional, Scagliotti, Giorgio V., additional, Ramlau, Rodryg, additional, Hanna, Nasser, additional, Vansteenkiste, Johan, additional, Yoh, Kiyotaka, additional, Groen, Harry J.M., additional, Heymach, John V., additional, Mandrekar, Sumithra J., additional, Okamoto, Isamu, additional, Neal, Joel W., additional, Heist, Rebecca S., additional, Planchard, David, additional, Pignon, Jean-Pierre, additional, Besse, Benjamin, additional, Besse, B., additional, Lacas, B., additional, Pignon, J.P., additional, Remon, J., additional, Berghmans, T., additional, Dahlberg, S., additional, Felip, E., additional, Berghmans, Thierry, additional, Dahlberg, Suzanne, additional, Felip, Enriqueta, additional, Garon, Edward, additional, Adjei, Alex A., additional, Heist, Rebecca, additional, and Remon, Jordi, additional

Published
2022
Full Text
View/download PDF

44. Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study

Author

Leal, T.A., Kotecha, R., Ramlau, R., Zhang, L., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L., Havel, L., Kalmadi, S., Ward, J., Andric, Z., Berghmans, T., Gerber, D.E., Kloecker, G., Panikkar, R., Aerts, J., Delmonte, A., Pless, M., and Langer, C.

Published
2024
Full Text
View/download PDF

45. 1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250

Author

Thomas, A., primary, Cappuzzo, F., additional, Ying, C., additional, Yamamoto, N., additional, Chen, Y., additional, Cortot, A.B., additional, Berghmans, T., additional, Reguart Aransay, N., additional, Shibata, Y., additional, Jianying, Z., additional, Yoshida, T., additional, Moulin, C., additional, Sarholz, B., additional, Ferrer-Playan, J., additional, Kalapur, A., additional, Bolleddula, J., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

47. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

Author

Girard, N., primary, Ponce Aix, S., additional, Cedres, S., additional, Berghmans, T., additional, Burgers, S., additional, Toffart, A.C., additional, Popat, S., additional, Janssens, A., additional, Gervais, R., additional, Hochstenbag, M., additional, Silva, M., additional, Burger, I., additional, Prosch, H., additional, Stahel, R.A., additional, Govaerts, A-S., additional, Pochesci, A., additional, Neven, A., additional, and Peters, S., additional

Published
2021
Full Text
View/download PDF

49. 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor

Author

Mezquita, L., Xenophontos, E., Pretzenbaher, Y., Sureda, C., Nadal, E., Al-Rabi, K., Rousseau Bussac, G., Ponce Aix, S., Sullivan, I.G., Calles Blanco, A., Cloarec, N., De Langen, J., Berghmans, T., Descourt, R., Hendriks, L., Garrido Lopez, P., Helland, A., Carcereny, E., Besse, B., and Dingemans, A-M.C.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results